HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
5.50
+0.28 (5.36%)
Jun 12, 2025, 4:00 PM - Market closed
HCW Biologics Stock Forecast
HCWB's stock price has decreased by -87.15% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for HCW Biologics stock has a target of 35, which predicts a 536.36% increase from the current stock price of 5.50.
Price Target: $35.00 (+536.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for HCW Biologics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $120 → $35 | Strong Buy | Maintains | $120 → $35 | +536.36% | May 29, 2025 |
| EF Hutton | EF Hutton | Strong Buy Initiates $360 | Strong Buy | Initiates | $360 | +6,445.45% | Jun 1, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $360 | Strong Buy | Reiterates | $360 | +6,445.45% | Apr 19, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $360 | Strong Buy | Reiterates | $360 | +6,445.45% | Mar 30, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $360 | Strong Buy | Reiterates | $360 | +6,445.45% | Mar 23, 2023 |
Financial Forecast
Revenue This Year
n/a
from 2.57M
Revenue Next Year
n/a
EPS This Year
-22.44
from -30.96
EPS Next Year
-22.03
from -22.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -23.10 | -22.68 | -24.78 |
| Avg | -22.44 | -22.03 | -24.07 |
| Low | -21.56 | -21.17 | -23.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.